Opinion

Video

R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial

Author(s):

Jae Park, MD

Jae Park, MD, reviews updated data from the ZUMA-3 trial on the use of the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia, noting high remission rates, management of side effects like cytokine release syndrome, and post-CAR-T consolidation, including transplant.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Related Content